Ionis Pharmaceuticals (NASDAQ:IONS) Price Target Cut to $70.00 by Analysts at Oppenheimer

Ionis Pharmaceuticals (NASDAQ:IONS) had its price target lowered by research analysts at Oppenheimer from $85.00 to $70.00 in a note issued to investors on Tuesday, Benzinga reports. The brokerage presently has an “outperform” rating on the stock. Oppenheimer‘s target price suggests a potential upside of 145.56% from the stock’s current price.

Several other research analysts have also issued reports on the company. Royal Bank Of Canada reduced their target price on Ionis Pharmaceuticals from $85.00 to $60.00 and set an “outperform” rating on the stock in a research report on Tuesday. Citigroup reissued a “buy” rating on shares of Ionis Pharmaceuticals in a report on Wednesday, October 21st. Morgan Stanley dropped their price target on Ionis Pharmaceuticals from $110.00 to $104.00 and set an “overweight” rating on the stock in a research note on Tuesday, September 8th. Weiss Ratings restated a “sell (d-)” rating on shares of Ionis Pharmaceuticals in a report on Thursday, October 15th. Finally, Canaccord Genuity Group cut their price objective on shares of Ionis Pharmaceuticals from $95.00 to $85.00 and set a “buy” rating on the stock in a report on Tuesday, September 8th. Nineteen research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $82.71.

Ionis Pharmaceuticals Stock Down 8.0%

NASDAQ:IONS traded down $2.49 during midday trading on Tuesday, reaching $28.51. 2,067,998 shares of the stock traded hands, compared to its average volume of 2,742,501. Ionis Pharmaceuticals has a 12-month low of $27.75 and a 12-month high of $86.74. The business has a 50-day moving average of $46.20 and a two-hundred day moving average of $65.63. The company has a debt-to-equity ratio of 3.07, a quick ratio of 7.73 and a current ratio of 7.89. The stock has a market capitalization of $4.74 billion, a PE ratio of -8.25 and a beta of 0.43.

Ionis Pharmaceuticals (NASDAQ:IONS) last announced its earnings results on Monday, November 9th. The company reported ($0.66) earnings per share for the quarter, beating the consensus estimate of ($1.23) by $0.57. The company had revenue of $242.72 million during the quarter, compared to the consensus estimate of $178.17 million. Ionis Pharmaceuticals had a negative net margin of 64.76% and a negative return on equity of 111.08%. Ionis Pharmaceuticals’s revenue was up 54.8% compared to the same quarter last year. During the same period last year, the firm earned ($0.80) earnings per share. On average, equities analysts forecast that Ionis Pharmaceuticals will post -3.62 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Ionis Pharmaceuticals news, EVP Shannon Devers sold 1,357 shares of the business’s stock in a transaction dated Friday, October 16th. The stock was sold at an average price of $43.54, for a total transaction of $59,083.78. Following the sale, the executive vice president owned 17,811 shares in the company, valued at approximately $775,490.94. The trade was a 7.08% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders own 1.81% of the company’s stock.

Institutional Investors Weigh In On Ionis Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the company. Edgestream Partners L.P. purchased a new stake in shares of Ionis Pharmaceuticals during the third quarter worth approximately $807,000. Ground Swell Capital LLC purchased a new position in shares of Ionis Pharmaceuticals in the third quarter worth about $547,000. Allworth Financial LP grew its stake in Ionis Pharmaceuticals by 79.8% during the 3rd quarter. Allworth Financial LP now owns 928 shares of the company’s stock valued at $41,000 after acquiring an additional 412 shares in the last quarter. Fisher Asset Management LLC grew its stake in Ionis Pharmaceuticals by 33.4% during the 3rd quarter. Fisher Asset Management LLC now owns 182,997 shares of the company’s stock valued at $8,171,000 after acquiring an additional 45,813 shares in the last quarter. Finally, Russell Investments Group Ltd. raised its holdings in Ionis Pharmaceuticals by 110.0% in the 3rd quarter. Russell Investments Group Ltd. now owns 170,799 shares of the company’s stock valued at $7,773,000 after acquiring an additional 89,480 shares during the last quarter. Institutional investors and hedge funds own 93.86% of the company’s stock.

Key Headlines Impacting Ionis Pharmaceuticals

Here are the key news stories impacting Ionis Pharmaceuticals this week:

• Positive Sentiment: Ionis reported third-quarter revenue of about $243 million, up roughly 55% year over year and above expectations. Its quarterly loss was also narrower than analysts had forecast. Read More.
• Positive Sentiment: DAWNZERA sales grew 40% to $37 million, providing a positive commercial update amid weakness in TRYNGOLZA’s launch. Read More.
• Negative Sentiment: Ionis cut its 2026 TRYNGOLZA sales outlook to approximately $50 million, down from its prior $100 million–$110 million target. The company cited slower-than-expected uptake and competitive pressure, undermining expectations for the drug’s commercial potential. Read More.
• Negative Sentiment: Ionis guided to 2026 revenue of $875 million–$900 million, below the roughly $921 million consensus estimate, adding to concerns about near-term growth. Read More.
• Negative Sentiment: Law firms announced investigations into potential investor claims related to Ionis, adding a legal overhang following the sales forecast reduction. These announcements concern potential claims and do not establish wrongdoing. Read More.
• Negative Sentiment: HC Wainwright and Needham lowered their price targets to $70 and $54, respectively, although both maintained Buy ratings. Read More. · Read More.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals is a biotechnology company that discovers and develops RNA-targeted medicines, with a focus on antisense oligonucleotides. Its medicines are designed to act on RNA and change the production of proteins linked to disease. The company’s research and development programs span neurological, cardiovascular, metabolic and rare diseases.

Ionis has developed medicines that it commercializes itself and products advanced or marketed with pharmaceutical partners. Its medicines and partnered products include treatments for conditions such as spinal muscular atrophy and transthyretin amyloidosis.